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1 INTRODUCTION 
 
1.1 OVERVIEW 
 
Only about half of the patients affected by locally advanced head and neck 
squamous cell carcinoma (HNSCC) and treated with post-operative RT-CT are 
alive after five years, indicating a substantial unmet medical need for 
improvement. In addition to the already known HPV16 status, new biomarkers 
are currently investigated in order to personalize treatment options and improve 
patients’ outcome. Evidence suggests that the chemokine pathway SDF-
1/CXCR4 play a key role in tumour development, progression and therapies 
resistance. The present study explores the prognostic value of these two 
biomarkers in a cohort of more than two hundred HNSCC patients treated with 
post-operative RT-CT. The results of the present study have been published 
and the full text publication is attached to the thesis [1].  
 
1.2 HEAD AND NECK CANCER 
 
1.2.1 Epidemiology 
 
Approximately 4% of the newly worldwide diagnosed malignant tumours are 
represented by head and neck cancers, with a large majority of squamous cell 
carcinomas [2]. Incidence of HNSCC varies geographically, even within the 
European Union, with countries showing higher incidence (e.g. Hungary, 
23/100.000) and others much lower (e.g. Greece or Cyprus, 3/100.000). In 
Germany in 2012, HNSCC incidence was 14,4/100.000 and mortality 
4,2/100.000 [3]. Almost 2/3 of the head and neck cancer patients are men, often 
with a history of alcohol and/or tobacco abuse. For this reason, patients with 
HNSCC have also a higher risk to develop other tumours, e.g. lung or 
oesophageal cancers. Even though tobacco and alcohol are the most common 
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risk factors, the incidence of HPV positive tumours especially in non-
smoker/drinker population is arising. The human papilloma virus, mostly the 
HPV-16 type, through the interaction of the viral oncoproteins E6 and E7 with 
tumour suppressor genes Rb and p53, can lead to development of cancer 
lesions. HPV-related tumours are more often located in the oropharynx, 
respond better to radio-chemotherapy and have a more favourable prognosis.  
 
1.2.2 Natural history and pattern of spread 
 
The local spread of the primary tumour depends mostly on the anatomical site, 
with more common muscle invasion and spread along muscle of facial planes, 
while bone structures represent a barrier and are infiltrated only in the most 
advanced stages of disease. The presence of perineural or vascular invasion 
(PNI, VI) is recognised as risk factor for a poorer outcome. Predicting the risk 
and the pattern of lymph node metastasis are crucial for the therapy choice and 
planning. The lymph node spread depends on different factors, among them 
tumour localisation, histology, T stage, PNI and VI. Generally, lateralized 
lesions have higher probability to spread to the ipsilateral lymph nodes, while 
tumours closed to or crossing the middle line are more likely to spread ipsi- and 
contralaterally. The CUP syndrome (carcinoma of unknown primary), 
characterized by initial presentation of disease with pathologic lymph nodes 
without evidence of primary lesion, is not uncommon among HNSCC patients 
(ca. 2-9%). Distant spread represents a late event which is more related to the 
N stage (circa 20-30% probability by N2-N3 tumours) than to the T stage and 
with the lung being the most commonly involved organ [4, 5]. 
 
1.2.3 Diagnostic work-up 
 
Initial signs and symptoms can vary, being dysphagia, weight loss, local pain 
and clinically visible lesions and adenopathies the most common. The local 
extent of disease is determined by the clinical examination with fibroscopy and 
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radiologically through computed tomography (CT) and magnetic resonance 
(MR). The MR, especially with contrast, allows high anatomical resolution: it 
defines the size of the primary tumour, its relationship with adjacent structures 
and gives information about the regional extent of disease. The CT-PET, 
through functional imaging, is able to identify with high sensitivity eventual nodal 
metastasis and has become a widely used tool for pre-treatment staging. Its key 
role has been demonstrated not only in the diagnostic work-up, but also to 
evaluate the response to the treatment [6]. Moreover, together with a chest-CT, 
PET-CT may detect distant metastasis. Before start of treatment, histology 
verification through biopsy is mandatory. Patients with CUP syndrome, 
additionally to the fine needle aspiration (FNA) or less frequent to the excisional 
biopsy, receive a complete endoscopic examination with multiple biopsies 
performance. Standard of care is also the HPV-DNA/p16 status. To decide the 
adequate treatment strategy a multidisciplinary team, formed by head and neck 
surgeons, radiation oncologists, medical oncologists, pathologists, radiologists, 
dentists, plastic surgeons and speech and swallowing therapists has to be 
involved. 
 
1.2.4 Staging 
 
The tumour stage helps in defining the therapeutic approach and predicting 
outcomes. It differs according to the involved site, but generally the T stage is 
based on the tumour size and the N stage on the size, number and localisation 
(ipsi- or also controlateral) of the pathologic lymph nodes. Stages I and II 
usually identify relatively small lesions without regional spread, while stages III 
and IV indicate loco-regionally advanced tumours or a metastatic disease. The 
present study was performed on the basis of the 7th TNM edition, that presents 
some differences respect to the latest 8th edition. Particularly, the new edition 
takes into account for the T staging of the oral cavity tumours, not only the 
tumour size, but also how deep the tumour infiltration is. For the pharynx 
cancers, the 8th edition distinguishes the oropharynx carcinomas HPV positive 
and HPV negative, reflecting the better outcomes of HPV positive tumour. 
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Regarding the N staging, the new edition separates the lymph nodes status in 
clinical (cN) and pathological (pN), considering not only the size and the 
laterality of the metastatic lymph nodes but also the presence of extranodal 
spread [7]. 
 
 
1.2.5 Treatment 
 
1.2.5.1 General principles 
 
HNSCC, excluding metastatic disease, can be treated with curative intent 
through surgery and/or radiotherapy. Chemotherapy alone is a palliative 
treatment, but it can be used as part of a curative strategy together with 
radiotherapy to increase the response rate and survival. Being the head and 
neck a region containing many structures for key functions as swallowing, 
breathing and speaking, the treatment choice should be based on the 
probability to achieve the highest tumour cure rate with the lowest morbidity 
rate, trying to avoid long-term functional (and cosmetic) deficits. Thus, patient’s 
will and a multidisciplinary discussion play an essential role in defining the 
treatment strategy. 
A surgical approach allows a pathological staging, a shorter treatment time, a 
limited non-tumoural tissue exposure to treatment and, by definition, a tumour 
resection (sometimes psychologically preferred by patients), but it can lead to 
permanent important dysfunctions. In cases where the oncological outcomes 
are assumed to be similar and surgery could inflict permanent functional 
defects, a radio (chemo) therapy is to be preferred. This is usually characterized 
by acute toxicities, but the late effects are often minimal if compared to a major 
surgery and functions as swallowing, breathing and speaking can be better 
preserved [5, 8]. While the management of the primary tumour lesion is relative 
straight forward (curative RT-dosis, i.e., according to a standard fractionation 
schedule, 66-70 Gy, or tumour excision in case of surgery), the management of 
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the neck is more complex. Different types of neck dissection as part of the 
surgical management can be performed. It includes radical neck dissection, 
modified neck dissection or selective neck dissection, according to the clinical 
initial disease presentation. Similarly, the radiation treatment of the neck, doses 
and volumes definition, is performed considering the macroscopic disease and 
the probability of the different lymph nodes levels to host microscopic 
metastasis, with the definition of usually two or three different target volumes.  
 
1.2.5.2 Surgery 
 
A head and neck surgeon with expertise in the field of oncology should perform 
the operation, planning the surgical procedure (tumour resection and 
reconstruction) to achieve tumour-free margins and the best possible functional 
and cosmetic outcomes. Usually, a surgical approach should be avoided when 
the tumour infiltrates structures like M. pterygoideus, base of skull, carotid 
arteries, skin, prevertebral fascia and nasopharynx [5]. En-block tumour 
resection with clear margins, defined as > 5 mm between the tumour and the 
resection margin, is the goal. Close margins (< 5 mm) and positive margins 
correlate with higher risk of relapse and should be avoided. In case of positive 
margins an adjuvant treatment with radio (chemo) therapy must be considered. 
Cranial nerves, if not macroscopically infiltrated and if preoperative functioning, 
should be preserved. As mentioned before, different types of neck dissection 
can be performed. A radical neck dissection removes the superficial and deep 
cervical fascia with all the lymph nodes from level I to level V, the 
sternocleidomastoid muscle, the omohyoid muscle, internal and external jugular 
veins, XI cranial nerve and submandibular gland. To avoid such a major surgery 
with subsequent important deficit and high risk of complications, when possible 
a modified neck dissection is performed, that spares the XI cranial nerve (type 
1), the cranial nerve and the internal jugular vein (type 2), the cranial nerve, the 
jugular vein and the sternocleidomastoid muscle (Type 3 or functional neck 
dissection). In both the radical and the modified (inclusive the functional) neck 
dissection lymph nodes of level I to V are removed. A selective neck dissection 
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is characterized by the removal of the high-risk lymph nodes, usually level II and 
III always, sparing, according to the disease presentation, level I and/or IV and 
/or V. For lateralized lesions, only an ipsilateral neck dissection, sparing the 
contralateral neck, can be considered, while for more central tumours a bilateral 
dissection is indicated. Even by clinically N0 tumours, an elective nodal 
dissection has to be evaluated, being the estimated risk of microscopic 
metastasis less than 20% by T1 tumours, but between 20 and 30% by T2 
tumours and more than 30% by T3-4 tumours [9]. By clinically N0 tumours, a 
selective neck dissection (levels I-III for oral cavity, levels II-IV for oropharynx, 
levels II-IV and eventually V) may be performed. By N1-N2 a selective or a 
comprehensive (modified or radical) dissection should be evaluated and by N3 
tumours a comprehensive neck dissection is the surgical standard [10]. Relative 
new frontiers of the surgical management of the neck concern the use of the 
sentinel lymph node biopsy for early stage (T1-2) oral cavity tumours [5]. Neck 
dissection is also indicated by a rest tumour after curative RT (CT) therapy, 
assessed by CT or PET-CT [11]. 
 
1.2.5.3 Radiotherapy 
 
Radiotherapy has been established for a long time as a curative treatment for 
HNSCC. During the last decades, advancements in treatment planning and 
delivery, together with the addition of chemotherapy and modified fractionation 
schedules, led to significant improvements of the oncological outcomes and 
minimization of late toxicity.  Target volumes definition became (and is 
becoming) more and more precise through the incorporation of functional (PET-
CT) and high resolution anatomical (MRI) information [12]. Intensity modulated 
RT (IMRT) techniques allow a better sparing of normal tissues and relatively 
new image guided RT (IGRT) methods, as cone beam CT, allow narrower 
margins for the definition of the target volumes. Together, IMRT and IGRT 
approaches led to a reduction of treatment-related toxicities. In the treatment 
planning phase, the gross tumour volume (GTV), when present, must be 
delineated for the tumour and for the nodal disease. A clinical target volume 
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(CTV) is then defined taking into account the risk of microscopic disease. 
Finally, the planning target volume (PTV) is determined considering the 
uncertainties due to patient’s positioning and (even though in H&N region is 
limited) organ motion. According to standard fractionation schedules, a radical 
RT treatment is performed with 66-70 Gy to the macroscopic disease, 60-66 Gy 
to the high-risk volume (lymph nodes clinically negative but at high risk of 
microscopic metastasis) and 50-54 Gy to the low risk volume. In the adjuvant 
setting, usually RT doses range between 60-66 Gy to the high risk volume and 
50-54 Gy to the low risk volume. A dose-volume histogram is carefully 
evaluated before treatment, to check the coverage of target volumes and the 
dose to organs at risks. Being the head and neck a region with many organs at 
risk, the final treatment plan is often a compromise between the optimal 
therapeutic doses and volumes and the probability of, especially late, toxicities 
(Figure 1.1).  
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Figure 1.1. Example of an IMRT treatment plan for a HNSCC patient treated 
with adjuvant radiotherapy. Below, the dose-volume histogram. Different 
planning target volumes, with the relative prescribed dose, are defined, 
according to the risk of regional involvement (here, 54 Gy, 60 Gy and 64 Gy, 
respectively PTV54, PTV60 and PTV64). Organ at risk, such as the left parotid 
and the spinal cord are spared.  
 
Chemotherapy applied concomitantly to radiation led, through a radiosensitizing 
effect, to significant improvements of loco-regional tumour control and survival 
of HNSCC patients and is now the standard of care for locally advanced 
tumours treated with primary RT and finds indications in different adjuvant 
scenarios. Since the present study was conducted on patients treated with 
adjuvant RT-CT, the next paragraph is focused on this combined approached 
without further description of primary RT-CT, palliative CT and target therapies. 
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1.2.5.4 Combined modalities: surgery and post-operative radio (chemo) 
therapy 
 
For patients treated with surgery and present with high risk (more than 20%, i.e. 
extranodal spread, positive margins and/or multiple involved lymph nodes) for 
locoregional relapse after surgery alone, adjuvant RT must be considered. In 
this setting, two significant even though not randomized studies provided 
evidence in favour of a postoperative radiation treatment. In the study 
conducted by Huang end colleagues 441 HNSCC resected patients were 
retrospectively analysed. 125 of them were found to have extranodal spread 
(ECE) and/or positive resection margins. 71 patients were treated with surgery 
alone and 54 with surgery and adjuvant RT. The univariate and multivariate 
analysis showed a significant difference in locoregional control (at 5 years 59% 
vs 31%, p=0.0001) and adjusted survival (72% vs 41%, p=0.001) in favour of 
the adjuvant treatment [13]. In a second significant study, Lundal et al. 
retrospectively analysed a cohort of 95 HNSCC patients treated with surgery 
and adjuvant RT and, through a matched pair analysis with HNSCC patients 
treated with surgery alone, found significant differences in terms of recurrence 
in the dissected neck (RR=5.82; P=0.0002), recurrence in any side of the neck 
(RR=4,72), cancer-related death (RR=2.21; P=0.0052) and death from any 
cause (RR=1.67; P=0.0182) in favour of adjuvant RT [14]. Thus, adjuvant RT 
improves locoregional tumour control and survival and is therefore the standard 
treatment in HNSCC patients treated with surgery and at high risk of relapse.  
The addition of CT to RT for patient with high-risk resected HNSCC was 
established later, though with higher level of evidence. Two randomized trials, 
EORTC [15] and RTOG [16], were published in 2004 in the New England 
Journal of Medicine and both showed a better loco-regional control and survival 
among patients treated with adjuvant RT-CT if compared with adjuvant RT 
alone. In the EORTC study, 334 patients were randomized between adjuvant 
RT alone (66 Gy standard fractionation) or RT-CT (66 Gy RT parallel to cisplatin 
100 mg/m2 every 21 days). With a median follow up of 5 years, fewer local and 
loco-regional relapses (31% after RT vs 18% after RT-CT, p=0.007), a better 
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progression-free survival (36% vs 47%, p=0.04) and overall survival (40% vs 
53%, p=0.02) were shown in patients treated with adjuvant RT-CT. Acute 
toxicity was higher in the RT-CT group, but without significant differences in 
terms of severe late toxicity. In the RTOG study, a total of 459 were randomly 
treated with adjuvant RT or RT-CT, with the same RT and CT schedules as in 
the EORTC study. With a shorter follow-up (circa 46 months) similar results, 
especially for locoregional control and disease-free survival, could be shown, 
even though no difference in terms of overall survival was detected. A German 
trial, where 440 patients were randomly assigned to receive adjuvant RT (66 Gy 
standard fractionation) or RT-CT (additionally to RT Cisplatin 20 mg/m2 and 5 
FU 600 mg/m2 on day 1-5 and 29-33) confirmed at 5 years a better loco 
regional tumour control (72% vs 89%, p=0,003) and progression free survival 
(50% vs 62%, p=0,024) for patients receiving the combined postoperative 
treatment, while no statistically significant differences where seen in terms of 
overall survival (49% vs 58%, p=0.1) [17]. Based on this evidence, high risk 
resected HNSCC are nowadays commonly treated with adjuvant RT-CT. 
 
1.3 CHEMOKINE SIGNALING AND CANCER 
 
1.3.1 Chemokines and their physiological role 
 
Chemotactic cytokines (chemokines) are small secreted molecules that bind to 
seven-transmembrane-domain of G-protein-coupled receptors. On the basis of 
the position of the first two cysteine residues, they are classified into four 
groups: CC, CXC, CX3C and XC, and their receptors are named accordingly. 
More than 50 ligands and 18 receptors have been so far described [18]. One of 
the most conserved chemokine pathways is represented by CXCL12 (also 
known as stromal derived factor 1, SDF-1) and his receptors CXCR4-CXCR7, 
that was found even in simple vertebrates like jawless fishes [19]. The reason of 
such a high evolutionary conservation is the key role that SDF-1/CXCR4-
CXCR7 and chemokines in general play in immune response and development. 
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Chemokines are produced by leucocytes, fibroblasts, endothelial cells and 
epithelial cells. They regulate both the innate (mediated by neutrophils, natural 
killer, dendritic cells and monocytes) and the adaptive (mainly T cells and B 
cells) immune response [20]. Through the so-called chemokine gradient, they 
attract immune cells to the site of inflammation. During embryogenesis, they are 
responsible for the migration of neurons, neural crest cells, germ cells, 
cardiomyocytes and hematopoietic stem cells. In addition, also in the adult, they 
play a crucial role in the angiogenesis process and their expression can be 
regulated by microenvironmental factors, like hypoxia. In fact, if in the 
embryonal development the axis SDF-1/CXCR4 is essential for the formation of 
the vascular system, inclusive big vessels like Aorta, in the adult SDF-1/CXCR4 
expression is induced by hypoxia inducible factor 1α (HIF-1α) and vascular 
endothelial grow factor (VEGF) in hypoxic areas, leading to migration of the 
endothelial precursor cells to the hypoxic site [19]. The ligand binding 
determines the phosphorylation of the receptor and the activation of several 
intracellular pathways, ending up in the nucleus with the transcriptions of genes 
regulating the interaction cell-extracellular matrix, cell motility, invasion, 
proliferation and survival [21]. While CXCR7 can bind also to other ligands, 
CXCR4 is one of the very few receptors that bind only to one chemokine, SDF-
1. Main pathways activated by SDF-1/CXCR4 are represented by PI3K/AKT 
and RAS/RAF/ERK. These are also ones of the most important pathways 
involved in cancer development and metastasis. 
 
1.3.2 Chemokines network in cancer 
 
CXCR4 expression has been observed in many haematological malignancies, 
such as AML, CML, B-ALL, C-ALL, follicular and non-Hodgkin lymphomas and 
multiple myeloma, as well as in solid tumours, like breast, prostate, thyroid, 
oesophageal, pancreatic, colo-rectal, ovarian, cervical, HNSCC, kidney, 
bladder, gliomas, sarcomas, melanoma and lung cancers [20, 22, 23]. The 
presence of chemokines in tumours has been described to regulate at least the 
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following key factors: infiltration of leucocytes and tumour immune response, 
angiogenesis, induction of proliferation and survival signals, tumour cell motility 
and migration [24]. 
 
1.3.2.1 Infiltration of leucocytes and tumour immune response 
 
Immune system is crucial in preventing tumour development. Even in cancer 
patients, the presence of tumour infiltrating lymphocytes has been shown to 
correlate with better prognosis [25]. On the other hand, chronic inflammation 
may lead to tumour development. In chronic inflammatory processes, the 
prolonged presence of high chemokine concentrations activates macrophages 
releasing immunosuppressive factors like IL-10 and TGF-β [24]. In fact, if type I 
macrophages are activated in response to microbes and parasites and have 
also antitumoral activity through the production of reactive oxygen species, an 
aberrant expression of chemokines and their receptors causes the activation of 
type II macrophages, owing immunosuppressing properties, in particular 
through TGF-β mediated suppression of the T-cell related antitumoral activity 
[20]. Additionally, chemokine signalling promotes migration of myeloid-derived 
suppressor cells from the bone marrow and the spleen to the tumour. These 
cells contribute to suppress the antitumoral T-cell activity [20]. Moreover, T cell 
function is dependent on the antigen presentation by dendritic cells. SDF-
1/CXCR4 signalling has been seen to downregulate dendritic cells motility and 
activity [24]. In addition to this “extrinsic pathway”, activated as a consequence 
of chronic inflammatory processes, tumour cells themselves are responsible of 
an “intrinsic pathway”, namely, due to different mutations and other types of 
genetic alterations, aberrant cells are able to produce chemokines and 
chemokines receptors creating an inflammatory tumour microenvironment that, 
as a loop, sustains itself independently of infectious conditions [26]. 
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1.3.2.2 Angiogenesis 
 
Different CXC chemokines promote angiogenesis, in an autocrine as well as 
paracrine manner. SDF-1 has been shown to be upregulated by HIF-1α, 
determining the recruitment of endothelial precursor cells to the hypoxic areas 
[19, 27]. VEGF is able to induce CXCR4 expression on endothelial cells 
precursors, rendering endothelial cells sensible to the chemokine gradients and 
therefore migrate and form new vascular structures [28]. Interestingly, in renal 
cell carcinomas with inactivating mutation of the von Hippel Lindau gene 
(tumour suppression gene inducing HIF-1α degradation under normal oxygen 
supply) HIF-1α is overexpressed and upregulates CXCR4 expression, that was 
seen to correlate with worse survival [29].  
1.3.2.3 Induction of proliferation and survival signals 
 
SDF-1/CXCR4 signal is mainly mediated by four intracellular pathways (Figure 
2.1). The phosphorylated receptor activates the way of RAS/RAF and MAP 
kinases as well as of PI3K and AKT. These pathways are also stimulated by 
many grow factors and are often altered in cancers. After being activated by 
RAS/RAF, ERK translocates to the nucleus, where it promotes the transcription 
of genes responsible for cell survival, proliferation and migration [30]. Similarly, 
after the interaction with PI3K generated phospholipids, AKT brings the signal to 
the nucleus, where it is phosphorylated by PDK1/2 and determines the 
transcriptions of genes involved in cellular growth, survival and cell cycle 
progression [31]. Interestingly, hyperactivation of PI3K/AKT is also involved in 
mechanisms of resistance to radio and chemotherapy [32]. A third pathway 
activated by SDF-1/CXCR4 is mediated by IP3, that increases the intracellular 
calcium concentration. Calcium signalling has been shown to play a role in cell 
proliferation, death, and invasion [33], as well as interfering with the response of 
cancer cells to radiation [34]. Finally, β arrestin can be responsible of the 
internalization of CXCR4.  
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Figure 2.1 SDF-1/CXCR4 intracellular activated pathways. 
1.3.2.4 Tumour cell motility and migration 
 
Chemotaxis occurs when cells move from a low level of chemokines 
concentration to a higher one (chemokine gradient). In response to extracellular 
chemotactic molecules, cells with proper receptors are chemosensitized, 
namely, they generate podia (membrane cell extensions) in the direction of the 
movement. This asymmetric organization of the actin and myosin filaments 
renders the cells polarized, with a “front” towards the higher chemokines’ 
concentration and a “back”. The cell then detaches and trails through integrin 
mediated adhesion and contraction of the actin/myosin filaments (locomotion). 
Within tumour tissues, four different types of chemotaxis have been described. 
In the amoeboid migration, a single cell squeezes through gaps in the 
extracellular matrix (ECM). The mesenchymal migration is typical of cells 
undergoing epithelial-mesenchymal transition and is characterized by elongated 
cells that exploits the lysis of the ECM through metalloproteinases (MMP). 
Migration of multiple cells can occur through the so-called chain migration, in 
which the movement is led by elongated cells being at front and driving other 
cells that remain attached to the leader ones through cell-cell junctions. Another 
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possibility of group migration is the streaming modality, in which each cell 
moves actively but following each other through cell-cell junctions. Interestingly, 
it has been shown that the leader cell is not always a tumour cell, rather often a 
stromal cell of the tumour microenvironment able to degrade the ECM (e.g. 
macrophages) [35]. The main chemokine axis regulating chemotaxis in cancer 
is SDF-1/CXCR4. Tumour cells that, through gene mutations or in response to 
microenvironmental factors like hypoxia, overexpress CXCR4 respond to 
chemokine gradients and acquire the ability to migrate (Figure 2.2). Studying 
cancer cell lines and mouse models of different tumour types, such as ovarian, 
breast, prostate, renal, lung cancer and melanoma, cells modified to express 
high levels of CXCR4 have been shown to own a higher metastatic potential 
[18].  
 
A last notably remark concerns the link between SDF-1/CXCR4 and cancer 
stem cells (CSCs). This chemokine axis is activated in CSCs of different tumour 
types and play a key role in clonogenicity and invasion potential as well as in 
resistance to treatment strategies as RT [36]. Self-renewal capacity of lung 
cancer stem cells has been shown in vitro and in vivo to be sustained by 
CXCR4, that, when blocked by the antagonist AMD3100, reduces the ability of 
lung cancer stem cells to form spheroid [37]. In vitro and in vivo studies showed 
also that prostate cancer cells CD133+/CD44+ (markers of CSC) adhere to the 
extracellular fibronectin under stimulation by SDF-1 and that prostate cancer 
stem cells proliferation is decreased when CXCR4 is inhibit by AMD3100 [38]. 
Similarly, SDF-1 has been seen to stimulate the formation of podia and 
migration in CD44+/CXCR4 positive HNSCC lines [39, 40]. 
 
1.3.3 SDF-1 and CXCR4 in head and neck cancer 
 
1.3.3.1 Preclinical evidence 
 
In vitro and in vivo studies have investigated SDF-1/CXCR4 mechanisms of 
actions in HNSCC. Under SDF-1 stimulation, CXCR4 positive oral squamous 
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cell carcinoma (OSCC) cell lines showed increased motility and invasion 
potential [41]. In different HNSCC cell lines, PI3K/AKT pathway was activated 
by SDF-1 in CXCR4 positive cells and migration and proliferation were shown to 
be enhanced; conversely, they were inhibited when CXCR4 was not functioning 
[42]. Invasion and metastasis mediated by NF-kB were enhanced by SDF-
1/CXCR4 in OSCC cell lines [43]. Tumour cell invasion and migration through 
modulation of MMP expression induced by SDF-1/CXCR4 have been shown in 
different HNSCC cell lines [44-46]. Hints concerning the involvement of SDF-
1/CXCR in the EMT through the activation of PI3K/AKT come from studies in 
OSCC [47] and xenograft mouse models [48]. In OSCC cell lines and in nude 
mice SDF-1 and CXCR4 were shown to be involved in development of lymph 
nodes metastasis through ERK1/2 or PI3K/AKT [49]. The same authors 
demonstrated SDF-1/CXCR4 involvement in the development of distant 
metastasis, through a paracrine action, which weas in contrast inhibited, with 
also a gain in survival of the mice, when AMD3100 was applied [50]. CXCR4 
knockdown was seen to induce cell cycle arrest and apoptosis in OSCC with 
anti-proliferative and anti-invasive effect [51, 52]. 
 
 
1.3.3.2 Clinical studies 
 
SDF-1/CXCR4 expression on tumour tissues derived from HNSCC patients has 
been described. Data indicate that this chemokine pathway correlates with 
enhanced metastatic potential and worse oncological outcomes [53]. Delilbasi 
et al. described CXCR4 expression in squamous cell carcinomas of the tongue 
from 23 patients, with higher expression in tumour cells of metastatic lymph 
nodes than in the primary tumour, while no expression was found in normal 
tongue tissue [54]. A significant correlation between CXCR4 expression and 
lymph node metastasis was found by Ishikawa and coll. among 90 patients 
affected by OSCC, 30% of those were CXCR4+ [41]. Katayama et al. showed 
that CXCR4 expression, which was identified in 29% of 56 OSCC patients, was 
stronger in patients with lymph node or distant metastasis and was a predictive 
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factor for worse cancer-specific survival (55% CXCR4 positive vs 85% CXCR4 
negative patients at 5 years) [42]. Tan and coll. detected SDF-1 and CXCR4 in, 
respectively, 54% and 40% of 30 patients affected by carcinomas of the larynx/ 
hypopharynx and found a significant correlation between CXCR4 high 
expression and lymph node and distant metastasis [44]. Among 30 patients 
affected by OSCC Uchida and coll. saw a higher SDF-1 expression in the 
metastatic lymph node cells than in the primary tumour and showed that SDF-1 
and CXCR4 were correlating with worse cancer-specific survival (25% SDF-1 
positive vs. 71% SDF-1 negative patients and 39% CXCR4 positive vs. 71% 
CXCR4 negative patients) [50]. Lymph node and distant metastasis were found 
to correlate with CXCR4 expression also in 25 HNSCC patients by Ueda et al. 
[55]. More aggressive features (e.g. lymph node metastasis and more advanced 
TNM stage) were described by Yin and coll. in patients affected by OSCC [56] 
and by Tao and coll. in patients affected by nasopharyngeal carcinoma [57]. 
CXCR4 but not SDF-1 expression was found to be a predictive factor for overall 
survival among 47 patients with carcinoma of the tongue (24% for CXCR4 
positive patients vs. 81% for CXCR4 negative patients at 5 years) [58]. Within 
233 HNSCC patients analysed by Rave-Fränk et al. high CXCR4 expression 
was found predictive for reduced distant metastasis-free survival and disease-
free survival but, in contrast, high SDF-1 expression was predictive for a better 
overall survival [59]. Clatot and coll. found among 71 HNSCC patients no 
correlation between CXCR4 and recurrence or survival and a poorer 
metastasis-free, disease-free and overall specific survival in patients with lower 
SDF-1 expression [60]. Leon et al., analysing 111 HNSCC patients, described a 
more complex pattern, with patients expressing high CXCR4 and low SDF-1 
values having a significantly worse regional recurrence-free survival rates [61].  
 
1.4 AIM OF THE STUDY 
 
Though advancement in RT planning and delivery and melioration of the 
oncological outcomes through modified fractionation schedules and addition of 
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concomitant CT, overall survival (OS) after adjuvant RT-CT in HNSCC patients 
remains unsatisfactory. One reason might be represented by the fact that the 
treatment choice is nowadays mostly determined by clinico-histopathological 
factors, which are apparently not enough to predict patients’ treatment 
response. New biomarkers are required for treatment individualization and the 
existing preclinical and clinical evidence suggest that SDF-1/CXCR4 axis is 
crucial for cancer development and progression. Moreover, this chemokine 
pathway may be involved in mechanisms that regulate tumour resistance to 
treatments, e.g. radiotherapy. Nevertheless, the published literature regarding 
the role of SDF-1 and CXCR4 in HNSCC patients is not conclusive, partially 
due to the small number of patients, the diversities in SDF-1/CXCR4 detection 
methods and because of the heterogeneity of patient and tumour 
characteristics, treatments and outcome parameters. Therefore, the goal of the 
present study was to explore the prognostic role of SDF-1/CXCR4 in a 
homogenous and large cohort of patients affected by locally advanced high-risk 
HNSCC treated with surgery and adjuvant CT-RT. The study was conducted 
retrospectively as part of a multicentre biomarker trial of the German Cancer 
Consortium Radiation Oncology Group (DKTK-ROG). The results of the study 
have been published [1]. 
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2 MATERIAL AND METHODS 
 
2.1 PATIENTS AND TREATMENT 
 
The ethical committees of all the DKTK-ROG centres (Berlin, Dresden, Essen, 
Frankfurt, Freiburg, Heidelberg, Tübingen, Munich- Technische Universität and 
Ludwig-Maximilians-Universität) approved the study. Patients with locally 
advanced squamous cell carcinoma of the oral cavity, oropharynx or 
hypopharynx treated between 2004 and 2012 with surgery and adjuvant RT-CT 
were retrospectively reviewed. The postoperative treatment was administered 
because of the presence of one or more of the following risk factors: stage pT4, 
>3 positive lymph nodes, positive microscopic resection margins, extracapsular 
extension. According to standard guidelines, all patients received platinum-
based CT and radiation treatment of the former primary tumour region and of 
the neck lymph nodes at risk regions. CT schemes, RT plans, formalin-fixed 
paraffin embedded (FFPE) tumour specimens as well as follow up data 
inclusive CT, MRI and/or PET images of the relapse, when present, had to be 
available. These data were collected centrally in the DKTK RadPlanBio Platform 
in Dresden. A period of 24 months was considered as minimum follow up. 
Finally, 221 patients were found to be eligible for inclusion. 
 
2.2 TISSUE SAMPLES, DETERMINATION OF HPV 16 DNA AND P16 
 
FFPE tumour materials retrieved after surgery were centrally (DKTK partner site 
Dresden) stained with haematoxylin and eosin for histology verification. Tissue 
microarrays (TMAs) were generated, having each core a diameter of 1-mm, and 
tumour content in each core was verified by expert pathologists. TMAs were 
sent to the DKTK partner centres for multibiomarker analyses.  
For the analysis of HPV16 DNA and p16, samples with <10% squamous cell 
carcinoma content were excluded. 214 patients were analysed. According to the 
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manufacturer’s instruction, HPV DNA was extracted from FFPE-sections, 
amplified by PCR and detected by hybridisation using QIAamp DNA FFPE 
tissue kit (Qiagen GmbH, Hilden, Germany), HotStarTaq Plus Master Mix 
(Qiagen GmbH) and LCD-Array HPV 3.5 kit (CHIPRON GmbH, Berlin, 
Germany), respectively. p16 expression was evaluated by 
immunohistochemistry and the staining was performed using the the CINtec 
Histology Kit (Roche mtm laboratories AG, Basel, CH), according to the 
manufacturer’s instruction. Overexpression, criterium of positivity, was 
considered when the staining was positive in more than 70% of the tumour 
sample. 
 
2.3 STAINING, IMAGING AND SCORING SYSTEM 
 
Immunofluorescence staining was used to evaluate SDF-1 and CXCR4 
expression. The staining was established under supervision of an experienced 
pathologist, using positive (tonsil tissue) and negative controls (PBS instead of 
primary antibody and anti-IgG from the same specie). TMAs staining was 
performed following deparaffinization, through Xilol, rehydration, through graded 
series of ethanol, and epitope-retrieval technique, by application of citrate buffer 
retrivial solution for 30 minutes at 600 Watts. According to the manufactures 
instructions, TSATM Kit T20912 (containing goat anti-mouse IgG and tyramide 
labelled with Alexa 488, Life Technologies GmbH, Molecular probes, Invitrogen, 
Darmstadt, Germany) was used to detect SDF-1 and TSATM Kit T20922 
(containing goat anti-rabbit IgG and tyramide labelled with Alexa 488, Life 
Technologies GmbH, Molecular probes, Invitrogen, Darmstadt, Germany) to 
detect CXCR4. Antibody dilutions were 1:100 for SDF-1 (mouse monoclonal, 
Clone 79018, R&D Systems, Minneapolis, USA) and 1:200 for CXCR4 (rabbit 
monoclonal [UMB2], Clone ab124824, Abcam, Cambridge Science Park Milton 
Rd, Milton, Cambridge, United Kingdom). Zeiss Axio Imager MI fluorescence 
microscope controlled by AxioVision 4.8 software (Carl Zeiss, Jena, Germany) 
was used to visualize the staining and obtain images of the TMAs. Whole TMA 
scans were performed using a motorised scanning stage and a monochrome 
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digital camera (AxioCam MRm, Carl Zeiss, Jena, Germany; Maerzhaeuser, 
Wetzlar, Germany, 400x (EC Plan Neofluar)). Different subcellular staining 
patterns, i.e. membrane and intracellular (including cytoplasmic and nuclear), 
could be identified and were confirmed by an expert pathologist. Criteria of 
positivity were the staining extent and intensity, evaluated only in the tumour 
areas. A staining intensity score with arbitrary thresholds was evaluated per 
each core as follow: negative (0), low (1), intermediate (2) and high (3). The 
score per each pattern type (membrane and intracellular) was calculated as the 
mean score of all the cores of the tumour specimen derived from each patient. 
At least one core having a score ≥2 (meaning a mean patient score >1) was 
considered as positive. This semi-quantitative analysis of the tissue staining 
was performed jointly by two observers blinded to the clinical characteristics 
and oncological outcome of the patients. In case of disagreement between the 
two observers a consensus was found. 
 
2.4 STATISTICAL ANALYSIS 
 
Events (relapse, metastasis and death) were calculated from the date of RT-CT 
start. Kaplan-Meier curves for loco-regional tumour control (LRC), distant 
metastasis free survival (DMFS) and OS were generated. Comparisons 
between staining results and clinico-pathological patients and tumours 
characteristics were performed using the Fisher’s exact test. Prognostic 
parameters were evaluated using univariate and multivariate analysis (Cox 
model). Hazard ratios and 95% confidence intervals were calculated. P-values 
<0.05 were considered statistically significant and between 0.05 and 0.1 as a 
trend. No correction for multiple testing was performed. To test whether the 
results were affected by the fact that the tumour material was coming from 
different institutions, we performed an additional univariate analysis for LRC and 
calculated the hazard ration (HR) for the different DKTK partner centres. The 
results were then tested for heterogeneity using ² test. The open-source 
software R (www.r-project.org, 3.2.3.) was used for statistical analyses, while 
  
26 
 
GraphPad Prism version 7 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com) was used for graphical representation. 
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3 RESULTS 
 
The median follow-up of the 221 patients included in the study was 47.3 months 
(range, 2.5-100 months). CT was administered with a median dose of 200 
mg/m2 and RT was consisting of a median dose of 50.4 Gy to the neck with a 
boost up to a median dose of 64 Gy to the former tumour region. The details for 
the entire population as well as the prognostic role of HPV16 have been 
reported by Lohaus and colleagues [62]. For the present study, some patients 
had to be excluded because of lack of tumour material. Finally, 201 patients 
were analysed for SDF-1 and 190 for CXCR4. For each patient, one to five 
cores were available. Patients and tumour characteristics as well as treatment 
details are reported in Table 3.1.  
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Table 3.1. Patients characteristics, SDF-1/ CXCR4 expression and treatment 
details for the 201 patients included in the present study [1]. 
 
Age (years) 57 (median) 24 (min) 76 (max) 
Gender Male 161 80,1% 
 
Female 40 19,9% 
Site Oral cavity 56 27,9% 
 
Oropharynx 116 57,7% 
 
Hypopharynx 29 14,4% 
pT stage T1 34 16,9% 
 
T2 92 45,8% 
 
T3 45 22,4% 
 
T4 30 14,9% 
R status Negative 113 56,2% 
 
Positive 87 43,3% 
 
Unknown 1 0,5% 
ECE Negative 95 47,3% 
 
Positive 106 52,7% 
p16 Negative 121 60,2% 
 
Positive 75 37,3% 
 
Unknown 5 2,5% 
HPV16 DNA Negative 134 66,7% 
 
Positive 67 33,3% 
icSDF1 Negative 148 73,6% 
 
Positive 53 26,4% 
icCXCR4 Negative 135 67,2% 
 
Positive 55 27,4% 
 
Missing 11 5,5% 
mSDF1 Negative 177 88,1% 
 
Positive 24 11,9% 
mCXCR4 Negative 176 87,6% 
 
Positive 14 7,0% 
 
Missing 11 5,5% 
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  Median Percentiles Range 
  
10% 25% 75% 90% Min Max 
Cisplatin dose (mg/m²) 200 100 200 200 240 100 300 
RT dose (Gy) Boost volume 64,0 60,0 63,8 66,0 66,0 56,0 68,4 
 
Per fraction 2,0 1,8 2,0 2,0 2,1 1,8 2,2 
 
Adjuvant volume 50,4 50,0 50,0 55,8 60,0 46,8 66 
 
Per fraction 2,0 1,8 1,8 2,0 2,0 1,8 2,1 
Time between surg. and RCT 
(weeks) 6,0 4,6 5,1 7,6 9,6 0,6 22,9 
Overall treatment time of RCT 
(days) 44,0 41,0 43,0 47,0 51,0 31,0 57,0 
Follow-up time (months) 46,2 9,7 30,1 60,5 70,4 2,5 100,1 
 
 
 
Different staining intensity and subcellular staining patterns, namely membrane 
and intracellular, were observed (Figure 3.1).  
Membranous SDF-1 (mSDF-1) positive staining was found in 24 (11.9%) 
tumours and membranous CXCR4 (mCXCR4) in 14 (7%). Intracellular SDF-1 
(icSDF-1) positive staining was detected in 53 (26.4%) tumours and intracellular 
CXCR4 (icCXCR4) in 55 (27.4%) (Table 3.1). The relationship between icSDF-1 
and icCXCR4 expression and clinic-pathological tumour characteristics are 
summarized in Table 3.2.  
A higher icSDF-1 expression was present within grade 2 (G2), HPV16 DNA and 
p16 positive tumours, while icCXCR4 positive staining was associated with G2 
tumours and lower pT-stages. 
No significant correlations between mSDF-1 or mCXCR4 with LRC, DMFS or 
OS were found (Table 3.3). High icSDF-1 expression was associated with 
significantly lower LRC, among all patients and within the HPV16 DNA negative 
subgroup (HR 2.67, 95% CI 1.29-5.54 and HR 2.54, 1.19-5.4, respectively) 
(Table 3.3 and Figure 3.2). A trend towards lower LCR rates in icCXCR4 
positive tumours was found (Table 3.3 and Figure 3.3). No correlation between 
icSDF-1 or icCXCR4 expression and DMFS or OS was found (Table 3.3). The 
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combined icSDF-1 and icCXCR4 expression showed a strong correlation with 
lower LRC (Table 3.3 and Figure 3.4). 
 
A)     
B)  
C)  
Figure 3.1. Representative images of SDF-1 immunofluorescent stained tumour 
sections. A) Intracellular staining (score 2). B) Membrane staining (score 3). C) 
Negative staining (score 0). SDF-1 is shown in green, DAPI in blue. Similar 
staining patterns and intensities were observed for CXCR4. Original image 
magnification: 400x [1]. 
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Table 3.2. Clinico-pathological characteristics and icSDF-1/icCXCR4 
expression. P-values for comparisons using the Fischer’s exact test, significant 
p-values in bold [1]. 
 
 
icSDF-1+ 
 
icSDF-1 - 
 
p icCXCR4+ 
 
icCXCR4- 
 
p 
Age 
          < Median (57 y) 23 43% 75 51% 0,42 30 55% 65 48% 0,52 
≥ Median 30 57% 73 49% 
 
25 45% 70 52% 
 Gender 
          M 43 81% 118 80% 1,00 42 76% 110 81% 0,43 
F 10 19% 30 20% 
 
13 24% 25 19% 
 Site 
          Oral cavity 18 34% 38 26% 0,31 19 35% 34 25% 0,41 
Oropharynx 26 49% 90 61% 
 
29 53% 82 61% 
 Hypopharynx 9 17% 20 14% 
 
7 13% 19 14% 
 pT stage 
          pT1-2 33 62% 93 63% 1,00 27 49% 89 66% 0,03 
pT3-4 20 38% 55 37% 
 
28 51% 46 34% 
 pN stage 
          pN0-1 12 23% 38 26% 0,71 12 22% 36 27% 0,58 
pN2-3 41 77% 110 74% 
 
43 78% 99 73% 
 Grading (3 missing) 
         G1 0 0% 5 3% 0,01 2 4% 3 2% 0,08 
G2 38 73% 75 51% 
 
37 69% 71 53% 
 G3 14 27% 66 45% 
 
15 28% 59 44% 
 Resection margin (1 missing) 
        R0 32 62% 81 55% 0,42 32 59% 73 54% 0,63 
R1 20 38% 67 45% 
 
22 41% 62 46% 
 ECE 
          No 25 47% 70 47% 1,00 22 40% 66 49% 0,34 
Yes 28 53% 78 53% 
 
33 60% 69 51% 
 HPV16 DNA 
          Negative 41 77% 93 63% 0,06 40 73% 88 65% 0,39 
Positive 12 23% 55 37% 
 
15 27% 47 35% 
 p16 (5/4 missing) 
         Negative 39 76% 82 57% 0,01 37 69% 78 59% 0,25 
Positive 12 24% 63 43% 
 
17 31% 54 41% 
 Smoking (69/67 missing) 
         Yes 27 84% 90 90% 0,36 29 85% 80 90% 0,53 
No (never) 5 16% 10 10% 
 
5 15% 9 10% 
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Figure 3.2: Kaplan-Meier curves for locoregional tumour control in all patients 
(A) and patients with HPV16 DNA negative tumours only (B), according to the 
SDF-1 intracellular expression [1]. 
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Figure 3.3: Kaplan-Meier curves for locoregional tumour control in all patients 
(A) and patients with HPV16 DNA negative tumours only (B), according to the 
CXCR4 intracellular expression [1]. 
 
A 
B 
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Figure 3.4: Kaplan-Meier curves for locoregional tumour control in all patients 
(A) and patients with HPV16 DNA negative tumours only (B) according to the 
SDF-1 and CXCR4 intracellular coexpression (double positive patients). 
 
 
 
 
A 
B 
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Table 3.3. Univariate analysis in all patients and patients with HPV16 DNA 
negative tumours only. Significant results in bold [1]. 
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In the multivariate analysis icSDF-1 was confirmed as strong negative 
independent prognostic factor for LCR among all patients and within the 
subgroup of HPV16 negative patients (Table 3.4). CXCR4 was not significantly 
correlated with LCR at the multivariate analysis and the combined expression, 
even though statistically significant, did not outperformed SDF-1 expression 
alone. 
 
Table 3.4. Multivariate analysis in all the patients and patients with HPV16 DNA 
negative tumours only. Significant results in bold [1]. 
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No significant heterogeneity of the effect of icSDF-1 and icCXCR4 expression 
on LRC was observed between the different DKTK institutions (p-value of 0.25 
and 0.33, respectively; Table 3.5). 
 
Table 3.5. Analysis of the effect of icSDF-1 and icCXCR4 expression on 
locoregional control and relative HR values for the different DKTK centres. The 
results were tested for heterogeneity using ² test and revealed a p-value of 
0.25 and 0.33 for icSDF-1 and icCXCR4 respectively, i.e. the null hypothesis 
that the HR are identically distributed over the centres is not to be rejected. 
    
icSDF1 pos icSDF1 neg 
 Center HR CI 
 
Events Total Events Total 
 1 Cox PH model did not converge 2 4 0 15 
 2 3,119 0,437 22,27 2 9 2 22 
2=6.5787
, p=0.25 
3 6,502 0,5826 72,57 2 5 1 22 
4 1,9094 0,5384 6,772 4 10 6 29 
5 1,7321 0,09752 30,76 1 4 1 12 
6 4,706 0,4229 52,37 1 4 2 24 
7 1,1962 0,1243 11,52 1 6 3 21 
8 Cox PH model did not converge 1 11 0 3 
 Overall 2,6733 1,29 5,54 14 53 15 148 
   
 
   
icCXCR4 pos icCXCR4 neg 
 Center HR CI 
 
Events Total Events Total 
 1 Cox PH model did not converge 2 4 0 15 
 2 3,46 0,49 24,59 2 7 2 22 
2=3.438
, 
p=0.3289 
3 Cox PH model did not converge 3 9 0 14 
4 0,66 0,14 3,11 2 9 8 27 
5 Cox PH model did not converge 0 3 2 12 
6 0,63 0,06 6,90 1 12 2 16 
7 2,87 0,40 20,41 2 7 2 20 
8 Cox PH model did not converge 1 4 0 9 
 Overal
l 2,02 0,97 4,21 13 55 16 135 
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4 DISCUSSION 
 
4.1 SDF-1/ CXCR4 EXPRESSION AS NEGATIVE PROGNOSTIC FACTOR  
 
In the present study, we investigated the prognostic value of the expression of 
the chemokine SDF-1 and his receptor CXCR4 in, to our knowledge, the largest 
and most homogeneous cohort of patients affected by locally advanced HNSCC 
treated with surgery and adjuvant RT-CT. The results have been published [1]. 
Our analysis indicates that patients with SDF-1 positive tumours have poorer 
LRC rates, while the impact of CXCR4 was not confirmed at the multivariate 
analysis. Interestingly, the prognostic value of SDF-1 on LCR was shown also 
within HPV negative tumours, suggesting SDF-1 as potential biomarker for 
future treatment modification in a known higher risk population, as HPV 
negative patients in comparison to HPV positive patients are. These results 
suggest that SDF-1 might play a role in conferring to the tumour cells resistance 
to postoperative RT-CT.  
We observed a membrane and an intracellular (cytoplasmic and nuclear) 
expression on SDF-1 and CXCR4, in linear with other studies. In HNSCC 
tumour specimens, Faber and colleagues noticed that CXCR4 and SDF-1 were 
expressed in the membrane and in the cytoplasm of the tumour cells [39]. 
Interestingly, in our study, the membrane expression had no prognostic value, 
while the intracellular expression in SDF-1 and, even though not confirmed in 
the multivariate analysis, of CXCR4 were negatively correlating with LCR. This 
might open to the speculation that SDF-1/CXCR4 play a significative role after 
their internalisation in the cytoplasm and translocation to the nucleus. 
Nevertheless, the value of the subcellular location of SDF-1/CXCR4 remains a 
matter of discussion. Some authors could detect SDF-1 and CXCR4 in the 
nucleus of tumour cells in patients-derived colorectal tumour tissues and found 
that their nuclear expression was a negative factor for patients’ survival [63-65]. 
On the other hand, studies conducted on lung cancer patients showed a 
positive correlation between the nuclear SDF-1/CXCR4 expression and the 
  
39 
 
clinical outcome, while the cytomembrane staining had a negative prognostic 
role [66, 67]. 
The prognostic value of SDF-1 and CRCXR4 in cancer patients has been 
described in different studies. In a meta-analysis comprising more than five 
thousand patients with different tumour histologies, Zhao and colleagues found 
that patients with CXCR4-positive tumours had a shorter progression free 
survival and overall survival in comparison with CXCR4 negative tumours [68]. 
Specifically regarding HNSCC, some authors have already investigating the role 
of SDF-1/CXCR4. Leon and coll. collected evidence from more than one 
hundred patients, including laryngeal cancers, treated with surgery and adjuvant 
RT or RT-CT or primary RT or RT-CT [61]. Low SDF-1 was found a negative 
prognostic factor for LRC, DMFS and OS and low SDF-1 and high CXCR4 was 
prognostic for more regional failures. Similarly, Clatot et al. identified low SDF-1 
expression as a negative prognostic factor for LRC, DMFS and OS analysing 71 
patients affected by tumour of the oral cavity, pharynx and larynx and treated 
with adjuvant RT or RT-CT, while they didn’t find any prognostic role of CXCR4 
[60]. A study with a large cohort of 233 patients treated with primary RT or RT-
CT, published by Rave-Fraenk and coll., showed that patients with high SDF-1 
expressing tumours had better OS while CXCR4 expression was prognostic for 
worse DMFS. No correlation with LRC was found [59]. Albert and coll. found 
that among 47 patients treated with surgery for a tumour of the mobile tongue, 
CXCR4 correlated with high-grade tumours, lymph node metastases, and 
microscopic nerve invasion and was predictive for worse OS, but this result was 
not confirmed in the multivariate analysis. No correlation between SDF-1 
expression and OS was found [58]. Among 30 patients affected by oral 
squamous cell carcinomas, Uchida et al. found that SDF-1/CXCR4 
overexpression in lymph node metastases was predictive for poor OS [50]. 
Katayama and coll. evaluated 56 patients affected by oral cavity tumours and 
treated with neoadjuvant RT-CT, surgery or RT alone and observed that 
CXCR4 positive tumours was prognostic for poor OS and cancer specific 
survival [42]. Altogether, these studies offer a conflicting evidence regarding the 
prognostic role of SDF-1 and CXCR4 in HNSCC. Some of them are based on 
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relatively small patients’ cohort [42, 50, 58] or include patients with tumour 
stage from I to IV and treated with different approaches (surgery alone, RT or 
RT-CT alone, surgery and adjuvant or neoadjuvant RT or RT-CT). SDF-
1/CXCR4 expression was sometimes assessed through RT-PCR and 
sometimes through immunohistochemistry. In some studies HPV status was not 
determined [42, 50, 58] or was reported only for some patients and no 
correlation with SDF-1/CXCR4 expression was described [60, 61]. In the study 
published by Rave-Frank and coll. p16 positive tumours showed on average a 
higher SDF-1/CXCR4 expression in comparison with p16 negative tumours, 
while in our study SDF-1 was on average lower in p16 positive tumours [59]. 
The differences between these studies and our results might have different 
explanations, such as different patients’ cohorts and methodological aspects, as 
follow. Many of the mentioned studies were conducted on patients affected by 
tumours of the oral cavity, that is less than one third of our cohort; moreover, 
some of them included laryngeal cancers, that we in contrast excluded. 
Differences in stage distribution and therapeutic management might also 
contribute to explain some discrepancies. Additionally, we used 
immunofluorescence and not immunohistochemistry or RT-PCR to detect SDF-
1 and CXCR4. In contrast with these studies, our results are based on a large 
and homogeneous cohort of patients enrolled in different german centres with 
well-defined inclusion and exclusion criteria and centrally revised clinical and 
follow up data. This might overcome potential bias, e.g. cohort effects, 
methodological problems and differences in treatment modalities. Besides these 
strength points, the current study presents some weaknesses. In particular, 
patients were collected retrospectively and the staining analysis was performed 
with arbitrary-defined thresholds. Additionally, even though the staining analysis 
was performed by two observers who were blinded to patients’ characteristics 
and outcomes, results might be affected by intrinsic errors of a subjective and 
not computational analysis. 
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4.2 MECHANISMS OF TUMOUR AGGRESSIVENESS AND RADIOTHERAPY 
RESISTANCE IN SDF-1/ CXCR4 POSITIVE TUMOURS 
 
The chemokine pathway represented by SDF-1/CXCR4 have been described in 
tumours of different type [20, 22, 23], inclusive HNSCC [53]. Many of the 
biological mechanisms underlying these clinical observations have been 
described. In general, SDF-1/CXCR4 axis is involved in stimulating tumour cell 
survival, proliferation and chemotaxis [69] and the evidence that not only tumour 
cells, but also cells of the tumour microenvironment such as fibroblasts, 
endothelial and tumour infiltrating leucocytes can produce chemokines and 
express their receptors, triggers the idea of the tumour tissue as a complex 
system that self-promotes growth, local invasion and metastasis [18]. More 
specifically, proliferation signals mediated by MAPK and AKT, increased 
integrin and TNF-α expression, enhanced MMP activity, induced angiogenesis 
and modulation of immune cells have been described as mechanisms 
underlying the actions of SDF-1/CXCR4 in tumours [24]. These factors might 
explain the more aggressive features of SDF-1/CXCR4 positive tumours per se. 
On the other hand, the poorer LRC rates that we observed among SDF-
1/CXCR4 positive patients after post-operative RT-CT might also be explained 
by a higher radiation resistance of these tumours. SDF-1/CXCR4 induced 
radiation resistance may be supported by different factors, i.e. AKT mediated 
signaling, ion channels modification, bone-marrow derived immune cells and 
mesenchymal cells migration, regulation of focal adhesion kinases and CD8 
positive T cells activity, as the following evidence has shown. One of the 
intracellular pathways activated by SDF-1/CXCR4 is represented by PI3K/AKT. 
In vitro and in in vivo studies have shown that constitutively activated AKT 
favours a quicker repair of the DNA double strand breaks induced by radiation, 
conferring to the tumour cells radiation resistance properties [32]. Another 
possible mechanism underlying radiation resistance in SDF-1/CXCR4 positive 
tumours is the modification, through IP3, of ion channels activity, which has 
been found to regulate the formation of free radicals in the radiation induced 
DNA damage process [34]. As observed in human squamous cell carcinoma 
xenografts, after radiation, the chemokine gradient created by SDF-1/CXCR4 
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induces migration of bone-marrow derived immune cells such as CD11b 
positive myelomonocytes to the tumour, contributing to radio-resistance [70]. 
The presence of CD11b positive myeloid-derived suppressor cells under high 
SDF-1 concentration was associated with faster tumour growth in p53null mice 
[71] and a reduced p53 activity has been shown to stimulate the migration of 
mesenchymal stromal cells from the bone marrow to the tumour through higher 
SDF-1 level [72]. SDF-1/CXCR4 might influence the treatment response 
through regulation of the expression of focal adhesion kinases (FAK), as 
suggested by studies conducted on breast cancer cells [73] and on three-
dimensional grown human HNSCC, where FAK overexpression induced by 
SDF-1 was responsible for radiation resistance through activation of ERK and 
AKT [74]. Additionally, in squamous cell carcinomas, FAK, under high 
chemokines concentrations, was responsible for inhibition of the anti-tumoural 
CD8 positive T cell activity [75]. CD8+ T cells proliferation and actions are 
enhanced by anti-programmed death-ligand 1 (PD-L1) drugs and some studies 
suggested a synergistic effect of anti-PD-L1 immunotherapy and anti-SDF-
1/CXCR4 target therapies [76, 77]. 
Different factors are known to regulate the tumour response to fractionated RT, 
i.e. tumour cells repopulation, reoxigenation, redistribution, repair of the 
radiation induced-DNA damage and intrinsic radiation sensitivity. Even though 
during RT the tumour volume may change, these variations depends mainly by 
cells that do not have clonogenic properties, which are the majority of the 
tumour cells. The goal of RT is to avoid the repopulation of the few tumour cells 
that might be responsible for a recurrence, namely cancer stem cells (CSCs) 
[78]. If the quantitative transplantation assay remains the goal to prove if cells 
are CSCs or not, some proteins expressed on the cell surface have been 
described and are now commonly accepted as CSCs markers, e.g. CD133, 
CD44, CD29 [79]. Interestingly, evidence indicates CXCR4 as a potential 
biomarker for radioresistant cancer stem cells [36]. It has been found 
overexpressed in glioma stem cells and, together with SDF-1, in perihypoxic 
gliomas areas, contributing to tumour cells aggressiveness and resistance to 
RT-CT induced cell death [80]. Faber et al. observed that high SDF-1 
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concentrations stimulated the formation of podia in CD44 and CXCR4 positive 
HNSCC cells, indicating that SDF-1/CXCR4 axis might play a key role in the 
interaction between CSCs and their supportive cells in the CSC niche [40]. 
Additionally, oxygen availability is required for tumour growth and relapse. After 
irradiation, sprouting angiogenesis from adjacent vessels is inhibited and the 
formation of new vascular structures is dependent on circulating bone marrow 
derived cells (BMDCs). Experimental gliomas and prostate tumour models have 
shown that in a post RT-hypoxic tumour, HIF-1α stimulates SDF-1 production, 
which in turn promotes, as already mentioned, the migration of BMDCs to the 
tumour, contributing to reoxigenation and tumour growth [81, 82]. Moreover, 
through pro-proliferation signals such as those transcripted by NFkB under the 
stimulation of SDF-1/CXCR4 [43], after RT, quiescent tumour cells might be 
triggered to re-entering in the cell cycle and proliferate. Besides playing a role in 
tumour cell repopulation, reoxigenation and maybe redistribution, we have 
already seen how SDF-1/CXCR4 can interfere with the ability of the tumour cell 
to repair the DNA DSBs induced by RT though AKT [32], another crucial factor 
for the tumour response to radiation. 
 
4.3 SDF-1/ CXCR4 AS TARGETABLE PATHWAY 
 
Given the crucial role that SDF1 and CXCR4 play in cancers, multiple agents 
targeting this pathway have been developed [83]. The most studied is 
AMD3100, a pharmacological antagonist of CXCR4 (pubchem CID 65015; also 
known as Plerixafor, Mozobil; Sanofi SA, Paris, France). Preclinical studies, 
including in HNSCC models, showed a decreased cell proliferation, motility, 
invasion and a reduced metastatic potential under treatment with AMD3100 [48, 
69, 84, 85]. Importantly, an increase in response to RT was observed after 
administration of CXCR4 antagonist in xenograft breast, lung and glioblastoma 
tumours [86-88]. In clinical studies, some CXCR4 antagonists were used as 
bone marrow stem cells mobilizers and were employed either alone or in 
combination with other systemic therapies for diseases like lymphoma, 
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leukaemia and myeloma [89, 90]. In vitro and in vivo studies suggest that 
treatment with CXCR4 antagonists favours the response to chemotherapeutic 
agents also in solid tumours, i.e. prostate cancer and glioblastoma [91, 92]. A 
phase I trial investigating the effect of a CXCR4 peptide antagonist 
(LY2510924) in combination with the anti-PD-L1 antibody Durvalumab 
(MEDI4736) in in advanced refractory solid tumours is ongoing 
(ClinicalTrials.gov identifier: NCT02737072). Another phase 1/2 study 
employing the CXCR4 inhibitor USL311 alone or in combination with Lomustin 
in patients affected by advanced solid tumours or relapse/recurrent 
glioblastoma is currently ongoing (ClinicalTrials.gov identifier: NCT02765165). 
Altogether, evidence supports the design of future studies, in which CXCR4 
antagonists might be investigated as radiosensitisers in patients affected by 
solid tumours, inclusive HNSCC, and treated with RT or RT-CT. 
 
4.4 SDF-1/ CXCR4 AND BIOLOGY-DRIVEN INDIVIDUALIZED 
RADIOTHERAPY 
 
Tumour stage is the main factor determining treatment choice in HNSCC 
patients. Many biomarkers have been identified and tested, but haven’t reached 
a clinical application yet. Since biological interpatient, but also intrapatient, 
differences are responsible for treatment resistance and recurrence, to 
incorporate biological information into treatment strategies is crucial to improve 
patients’ outcome. Importance and efficacy of biology-driven RT were shown 
among HNSCC patients in the last decades, by applying accelerated 
fractionated RT schedules, using hypoxia modifiers and adding concomitant CT 
to RT. Historically, standard fractionated RT alone was known as curative 
treatment for HNSCC, but with survival rates of approximately 30% at five years 
[93]. Alternative fractionations, i.e. accelerated and accelerated 
hyperfractionated schedules, with or without concomitant boost, reduce the 
overall treatment time and compensate the tumour (stem) cells repopulation. 
Applied to patients in clinical studies, they have been seen to correlate with 
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better oncological outcomes, by higher acute but similar late toxicity [94-96] and 
became the standard of care in many institutions worldwide. Hypoxic tumour 
cells are known to be more radioresistant and the presence of hypoxic tumour 
regions is crucial for RT response and tumour control, especially in HNSCC 
[97]. Efforts to reduce the hypoxic tumour content have been made, e.g. 
through the addition of hypoxia-modifying drugs as Nimorazole. A better 
response was observed, but their use is still limited [98]. Approaches of dose-
escalation on the hypoxic areas have been tested and appear promising [99]. 
Among, HNSCC, the significance of finding new biomarkers is exemplified by 
HPV16. Since its importance as prognostic factor was established, new trials 
have been opened to investigate the possibility of a de-escalation of the RT 
dose (e.g. De-escalation of adjuvant radio (chemo) therapy for HPV-
positive head and neck squamous cell carcinomas: a phase I study to reduce 
late toxicity, ClinicalTrials.gov identifier: NCT03396718). Patients’ stratification 
on the basis of prognostic and predictive biomarkers may lead in the future to 
individualized-biology driven RT.  
The DKTK-ROG aims to identify the most significant biomarkers as basis for RT 
interventions and, within this project, we conducted the present hypothesis-
generating study, investigating the prognostic potential of SDF-1/CXCR4 in 
HNSCC patients. Our exploratory results needed validation, which we 
performed in a cohort of HNSCC patients treated with primary RT-CT [100]. 
With the same methods of the present study, we could confirm the negative 
prognostic role of SDF-1 but also of CXCR4 for LRC. Additionally, we observed 
that these two biomarkers were correlating with a poor OS. Analysing the 
tumour material of the HNSCC patients included in the retrospective 
postoperative and primary cohorts, other partner groups within the DKTK-ROG 
showed the prognostic role of HPV16 DNA, p16 expression, CD8+ tumour-
infiltrating lymphocytes, expression of cancer stem cells markers, PD-1/PD-L1 
expression, Heat shock protein 70, tumour-infiltrating NK cells, hypoxia-
associated gene signatures and genetic alterations [62, 101-108]. The DKTK-
ROG is currently running the HNprädBio study, where the prognostic value of 
SDF-1/CXCR4 and other biomarkers might be validated in prospectively 
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enrolled HNSCC patients. Moreover, an analysis of all these promising 
biomarkers is currently ongoing, aiming to reveal the most promising ones and 
design future biology-driven interventional trials. 
 
4.5 CONCLUSION 
 
In our study, we demonstrated the negative prognostic role of the chemokine 
pathway SDF-1/CXCR4 in patients affected by locally advanced HNSCC 
treated with surgery and adjuvant RT-CT. Our data are still exploratory and 
need to be validated in a prospectively collected patients’ cohort. Nevertheless, 
they appear promising and support further investigations of the SDF-1/ CXCR4 
axis in HNSCC patients, aiming to stratify patients on the basis of biomarkers 
expression, for a biologically individualized RT-CT. Moreover, it represents a 
potential therapeutic target to overcome treatment resistance.  
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5 SUMMARY 
 
Outcomes of patients affected by locally advanced head and neck squamous 
cell carcinomas (HNSCC) and treated with surgery and adjuvant radio-
chemotherapy are still unsatisfactory, being the overall survival (OS) still settled 
around 50% at five years, with poor outcomes especially among HPV negative 
patients. Therefore, patients’ stratification based on biomarker profiles is 
required for personalised therapies. SDF-1/CXCR4 is known as the most 
important chemokine pathway involved in tumour development, progression and 
metastasis. Nevertheless, no clear data exist regarding the role of SDF-
1/CXCR4 among HNSCC patients. The present study aims to investigate the 
prognostic value of SDF-1 and CXCR4 in a large and homogeneous cohort of 
HNSCC patients treated with post-operative RT-CT, as part of a multicentre 
biomarker study within the German Cancer Consortium Radiation Oncology 
Group. The results of the study have been published [1]. 
221 patients affected by stage III and IVA HNSCC of the oral cavity, oropharynx 
and hypopharynx were treated with surgery and adjuvant RT-CT. Tumour 
microarrays with the post-surgical tumour material were generated and stained 
for SDF-1 and CXCR4 using immunofluorescence. 201 patients were analysed 
for SDF-1 and 190 for CXCR4.  
The univariate and multivariate analyses showed that higher SDF-1 intracellular 
expression significantly correlated with poor locoregional control (LRC) in the 
whole patients’ cohort as well as in the HPV16 negative patients. Higher 
CXCR4 intracellular expression correlated with poor LRC in the univariate 
analysis, but this trend was not confirmed in the multivariate analysis. Not high 
SDF-1 nor high CXCR4 expression correlated with distant metastasis free 
survival or OS. 
In summary, we could show for the first time in a large and homogeneous 
cohort of HNSCC patients treated with adjuvant RT-CT that SDF-1 correlates 
with worse LRC. These results are exploratory and need to be validated 
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prospectively, but support further investigation of SDF-1/CXCR4 as potential 
biomarker for treatment individualization and as a target to overcome resistance 
to RT.  
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6 ZUSAMMENFASSUNG 
 
Die Prognose von Patienten mit lokal fortgeschrittenen 
Plattenepithelkarzinomen im Kopf-Hals-Bereich, die mit einer chirurgischen 
Intervention und einer adjuvanten kombinierten Radiochemotherapie behandelt 
werden, ist mit einer 5-Jahres-Überlebensrate von 50% noch nicht 
zufriedenstellend. Dies gilt insbesondere für HPV negative Patienten. Der 
Stratifizierung von Patienten mit Hilfe von Biomarker-Profilen kommt daher eine 
besondere Bedeutung für personalisierte Therapien zu. SDF-1/CXCR4 ist dabei 
der wichtigste Chemokin-Pathway in der Tumorgenese, Tumorprogression und 
Metastasierung. Nichtsdestotrotz liegt keine klare Datenlage zur Rolle des SDF-
1/CXCR4-Pathways bei Plattenepithelkarzinom-Patienten im Kopf-Hals-Bereich 
vor. Die vorgelegte Studie untersucht den prognostischen Wert von SDF-1 und 
CXCR4 in einer großen und homogenen Kohorte von Plattenepithel-
Karzinomen im Kopf-Hals-Bereich, die mit einer postoperativen kombinierten 
Radiochemotherapie im Rahmen einer multizentrischen Biomarker-Studie der 
Deutsches Konsortium für Translationale Krebsforschung- RadioOncology 
Group (DKTK-ROG) behandelt wurden. Die Ergebnisse wurden publiziert [1]. 
Insgesamt 221 Patienten mit Mundhöhlen-, Oro- und Hypopharyxkarzinomen im 
Stadium III und IVa wurden mit einer chirurgischen Intervention und einer 
adjuvanten Radiochemotherapie behandelt. Tumor-Microarrays vom 
Resektionsmaterial wurden untersucht und eine Immunfluoreszenz-Färbung 
spezifisch für SDF-1 und CXCR4 durchgeführt. 201 Patienten wurden für SDF-1 
und 190 für CXCR4 untersucht.  
Univariate und multivariate Analysen zeigten, dass eine höhere intrazelluläre 
Expression von SDF-1 signifikant mit einer schlechteren lokoregionären 
Kontrolle (LRC) sowohl in der gesamten Kohorte als auch in der Gruppe der 
HPV-negativen Patienten korreliert war. Eine höhere intrazelluläre Expression 
von CXCR4 korrelierte mit einer schlechteren lokoregionären Kontrolle in der 
univariaten Analyse; dieser Trend konnte in der multivariaten Analyse jedoch 
nicht bestätigt werden. Weder eine hohe SDF-1- noch eine hohe CXCR4-
Expression korrelierten mit Metastasen-freiem Überleben oder 
Gesamtüberleben. 
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In der vorliegenden Studie konnten wir zum ersten Mal in einer großen und 
homogenen Kohorte von Patienten mit Plattenepithelkarzinomen im Kopf-Hals-
Bereich, die mit Operation und postoperativer Radiochemotherapie behandelt 
wurden, zeigen, dass SDF-1 mit einer schlechteren lokoregionären Kontrolle 
korreliert. Diese Ergebnisse sind explorativ und sollten im Verlauf weiter 
validiert werden. Dennoch sind SDF-1 und CXCR4 vielversprechende 
Kandidaten als potentielle Biomarker für die Individualisierung von Therapien 
und als Ansatzpunkt zur Überwindung von Strahlenresistenz. 
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